

## ImaCor Announces All-In-One Haemodynamic Management Platform



ImaCor Inc., the developer of the world's first and only haemodynamic transesophageal echocardiography (hTEE™) technology, has just announced the release of its all-in-one platform for advanced haemodynamic management. ImaCor is engaged in the designing, manufacturing and distribution of advanced solutions for haemodynamic assessment in the critical care environment. Their goal is to improve patient outcomes and to optimise the utilisation of healthcare resources.

The company has secured 510(K) clearance from the FDA to market a transthoracic echocardiography (TTE) probe. This is the first-of-its-kind platform for haemodynamic management.

ImaCor's all-in-one haemodynamic management platform is comprised of:

- hTEE, enabled by the ClariTEE® probe that can be left indwelling for 72-hours and has been proven in multiple studies to change management in 66% of critical care patients;
- hTTE™, a transthoracic probe for complementary haemodynamic management;
- Haemodynamic trending, displaying cardiac filling and function data over time in a dashboard format;
- Sizeable image quality improvements with 7 mHz resolution at 18 cm depth; and
- Zura<sup>™</sup> ultrasound systems, including the Zura EVO-1, the latest model in the Zura EVO<sup>™</sup> family to offer new advanced processing for high definition imaging.

According to Nicholas Cavarocchi MD, FACS, FCCP, Director of the Surgical Critical Care Unit at Thomas Jefferson University Hospital, "I am impressed with the significant image quality improvements of ImaCor's all-in-one haemodynamic management platform – it provides the whole picture in critical care. Our time to stability with ImaCor's technology has proven to be cutting edge."

Robert N. Sladen, MD, FCCM, Chief of the Division of Critical Care at Columbia University is also very positive about the platform and is confident that the continuous availability of hTEE™and the ability to use hTTE will provide additional benefits to their advanced haemodynamic management program.

The CEO of ImaCor Inc., Peter Pellerito is confident that the new platform will deliver higher level of capabilities to the customers and will also help save time, money and lives.

Source: ImaCor Inc.

Image Credit: ImaCor Inc.

Published on: Wed, 26 Nov 2014